Machine Learning-Guided Engineering of High-Affinity Cross-Reactive Antibodies with Minimal Mutations
A Deep Mutational Scanning-coupled deep learning strategy to engineer potent cross-reactive antibodies with minimal sequence divergence that retained PD-1/PD-L1 blockade and demonstrated therapeutic activity in a mouse tumor model is developed.